此案的细节令人吃惊。美国检方指控称,GSK为推荐帕罗西汀的儿童精神科医生提供豪华旅游。GSK让人在期刊上刊文,刻意淡化该药的风险。它还企图误导美国食品药品监督管理局(FDA),不让后者掌握到底有多少青少年在研究试验中因服用帕罗西汀而做出伤害自身的行为或企图自杀。
For these and charges related to other drugs, GSK this month pleaded guilty and agreed to pay $3bn to settle its criminal and civil liabilities.
面对上述指控及与其他药品相关的指控,GSK本月承认自己存在过失,并同意支付30亿美元了结相关的刑事和民事责任。
It was the biggest healthcare fraud settlement in US history and nearly seven times as much as Barclays had to pay for its Libor shenanigans. Yet there have been no televised parliamentary grillings of GSK’s bosses, its chief executive has not had to resign and there has been little public fuss.
这是美国历史上最大的一起医疗欺诈和解案,其和解金几乎相当于巴克莱Libor操纵案和解金的7倍。然而,国会并没有对GSK的老板们进行带电视直播的质询,GSK的首席执行官并没有被迫辞职,公众也没有过分关注此事。
Why not? One reason is that most of the misbehaviour took place until 2003, five years before Sir Andrew Witty was appointed GSK chief executive. He has overhauled the US operations, replaced managers and ended the link between sales staff’s incentives and prescription volumes.
【巴克莱Libor操纵案为何惹众怒?】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15